Drugs / Immuno-AG
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00001043 | ? → May 1997 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00000633 | ? → Oct 1998 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Immuno-AG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001043 ↗ |
| Known as | MN rgp160 vaccine | “AMENDED 8/94: To expand the safety and immunogenicity profile of MN rgp160 vaccine (Immuno-AG) by administering a higher dose (800 mcg) at 0, 1, 6, and 12 months and 0, 2, 8...” NCT00001043 ↗ |
| Modality | Vaccine | “Immuno-AG recombinant gp160 vaccine” NCT00000633 ↗ |